Purpose: To retrospectively compare subjective postirradiation xerostomia scores of patients who received concomitant oral pilocarpine during radiotherapy for head and neck cancer with a similar cohort who did not receive pilocarpine. Methods and materials: Between January 1998 and May 1998fifteen patients received 5 mg Salagen three times per day beginning on the first day of radiotherapy and continuing for 3 months. The control cohort had not received this medicine. Comparison of the radiation induced xerostomia and its consequences (difficulties with swallowing, eating, speech and sleep, worsening of oral comfort) was carried out by means of subjective questionnaire after 3 months p-om the beginning of the irradiation. Results: In the cohort who received medicine total xerostomia did not occur. Initial symptoms of partial form developed 1 week later compared to the control patients. The same observation applied to the case of mucositis. Evaluation of the parameters of questionnaires showed two times better results in the Salagen group. Side effects of the drug were mild and temporary. Conclusions: This retrospective study demonstrated that Salagen is a very effective compound in the treatment of the irradiation caused xerostomia and its consequences.
|Translated title of the contribution||Investigation of the protective effect of pilocarpine hydrochlorid (Salagen) during radiotherapy on patients with head and neck cancer|
|Number of pages||3|
|Publication status||Published - dec. 1 1999|
ASJC Scopus subject areas